Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

1. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Signal - Common osteoporosis drugs may prevent breast cancer spreading to bone Dissemination Centre Discover Portal NIHR DC Discover Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However

2019 NIHR Dissemination Centre

2. Prompts for GPs may improve diagnosis and treatment of osteoporosis

Prompts for GPs may improve diagnosis and treatment of osteoporosis Signal - Prompts for GPs may improve diagnosis and treatment of osteoporosis Dissemination Centre Discover Portal NIHR DC Discover Prompts for GPs may improve diagnosis and treatment of osteoporosis Published on 30 August 2016 Prompts for GPs with education and reminders for patients may improve “guideline consistent behaviour” and diagnosis and treatment of osteoporosis. Similar techniques aimed at improving GP management (...) or the disadvantaged who might benefit more. Share your views on the research. Why was this study needed? Musculoskeletal conditions such as osteoporosis, back pain and arthritis are common causes of pain and disability in the UK. One in six adults lives with a chronic musculoskeletal condition. Every year, over 20% of people consult their GP about musculoskeletal problems. Musculoskeletal conditions are a major cause of health system spending. In 2009-10, the NHS spent £4.76 billion in this area; this is more

2019 NIHR Dissemination Centre

3. Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain

Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Signal - Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Dissemination Centre Discover Portal NIHR DC Discover Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Published on 13 December 2016 Injecting cement into osteoporotic spinal fractures within six weeks reduces pain in the first few (...) available in some centres. Share your views on the research. Why was this study needed? Worldwide, an estimated 1.4 million people with osteoporosis experience vertebral fractures. Most osteoporotic vertebral fractures are treated conservatively with painkillers, bed rest and mobility exercises as function improves. However, painkillers and prolonged bed rest can both have adverse effects in older people. Vertebroplasty involves injecting special cement into the broken vertebrae to relieve pain

2019 NIHR Dissemination Centre

4. Osteoporosis. (PubMed)

Osteoporosis. Fractures resulting from osteoporosis become increasingly common in women after age 55 years and men after age 65 years, resulting in substantial bone-associated morbidities, and increased mortality and health-care costs. Research advances have led to a more accurate assessment of fracture risk and have increased the range of therapeutic options available to prevent fractures. Fracture risk algorithms that combine clinical risk factors and bone mineral density are now widely used (...) in clinical practice to target high-risk individuals for treatment. The discovery of key pathways regulating bone resorption and formation has identified new approaches to treatment with distinctive mechanisms of action. Osteoporosis is a chronic condition and long-term, sometimes lifelong, management is required. In individuals at high risk of fracture, the benefit versus risk profile is likely to be favourable for up to 10 years of treatment with bisphosphonates or denosumab. In people at a very high

2019 Lancet

5. The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper

The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper - Hill - - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search (...) The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free Access The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper Department of Haematology, Leeds Teaching Hospitals, , Leeds, UK Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, , Manchester, UK

2019 British Committee for Standards in Haematology

6. Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. (PubMed)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. 30304108 2018 12 11 2018 12 11 2359-4292 62 4 2018 Aug Archives of endocrinology and metabolism Arch Endocrinol Metab Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. 438-445 S2359-39972018000400438 10.20945/2359-3997000000060 (...) This study evaluated the effects of combination therapy of curcumin and alendronate on BMD and bone turnover markers in postmenopausal women with osteoporosis. In a randomized, double-blind trial study, 60 postmenopausal women were divided into three groups: control, alendronate, and alendronate + curcumin. Each group included 20 patients. Total body, total hip, lumbar spine and femoral neck BMDs were measured by dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of therapy. Bone

2018 Archives of endocrinology and metabolism

7. Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia

Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia 30359476 2018 10 25 1532-5415 2018 Oct 25 Journal of the American Geriatrics Society J Am Geriatr Soc Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia. 10.1111/jgs.15607 To examine the effect of 25-hydroxyvitamin D

2018 EvidenceUpdates

8. Denosumab (Prolia) and osteoporosis: an increasingly unfavourable harm-benefit balance

Denosumab (Prolia) and osteoporosis: an increasingly unfavourable harm-benefit balance Prescrire IN ENGLISH - Spotlight ''Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance '', 1 November 2018 {1} {1} {1} | | > > > Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |    (...) |   |   |  Spotlight Denosumab (Prolia°) and osteoporosis: an increasingly unfavourable harm-benefit balance Reports of sometimes serious adverse effects tilt the harm-benefit balance of denosumab in the treatment of osteoporosis. Denosumab is authorised in some cases of osteoporosis and bone metastases. As expected from the pre-market evaluation of denosumab, reports of adverse reactions related to disruption of the immune system attributed to denosumab are accumulating. To date

2018 Prescrire

9. Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study

Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study 30281143 2018 10 03 1532-5415 2018 Oct 03 Journal of the American Geriatrics Society J Am Geriatr Soc Association Between Cataract and Risks of Osteoporosis and Fracture: A Nationwide Cohort Study. 10.1111/jgs.15626 To evaluate the association between cataract and cataract surgery and risks of osteoporosis and fracture. Nationwide population-based retrospective cohort study. Taiwan's National Health (...) Insurance Research Database. Individuals with (n=57,972) and without (n=57,972) cataracts. Individuals with and without cataracts were matched 1:1 for age, sex, and index year. Those with cataracts were further divided into cataract surgery and nonsurgery groups. Incidences and hazard ratios (HR) for risks of developing osteoporosis and fracture were calculated using Cox proportional hazard regression models. During mean follow-up of 6.4 years, 17,450 participants with cataracts and 12,627 without

2018 EvidenceUpdates

10. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial (PubMed)

Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial 30381400 2018 12 07 2473-9537 2 21 2018 Nov 13 Blood advances Blood Adv Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. 2837-2847 10.1182/bloodadvances.2018023085 Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (...) (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalassemia (TDT)-induced osteoporosis are rather limited. Thus, we conducted a randomized, placebo-controlled, double-blind, phase 2b clinical trial to evaluate DNM in TDT osteoporosis. Patients were assigned to receive either 60 mg DNM (n = 32) or placebo (n = 31) subcutaneously on day 0 and 180 during a total of 12 months

Full Text available with Trip Pro

2018 Blood advances

11. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: September 2018 Last updated: October 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density, which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female sex, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m²), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

2018 BMJ Best Practice

12. Correlation between skin and bone parameters in women with postmenopausal osteoporosis: A systematic review (PubMed)

Correlation between skin and bone parameters in women with postmenopausal osteoporosis: A systematic review 30237903 2018 11 14 2058-5241 3 8 2018 Aug EFORT open reviews EFORT Open Rev Correlation between skin and bone parameters in women with postmenopausal osteoporosis: A systematic review. 449-460 10.1302/2058-5241.3.160088 Skin and bone share similarities in terms of biochemical composition.Some authors have hypothesized that their properties could evolve concomitantly with age, allowing (...) EFORT Open Rev 101695674 2058-5241 ageing bone mineral density epidemiology menopause osteoporosis skin ICMJE Conflict of interest statement: T. Begué declares board membership of EFORT, SOFCOT and GETRAUM; consultancy for Stryker Trauma; payment for lectures from Orthofix International; payment for travel and accommodation expenses from SMACOT and SICOT, activities outside the submitted work. 2018 9 22 6 0 2018 9 22 6 0 2018 9 22 6 1 epublish 30237903 10.1302/2058-5241.3.160088 10.1302_2058

Full Text available with Trip Pro

2018 EFORT open reviews

13. Osteoporosis

Osteoporosis Top results for osteoporosis - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for osteoporosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

2018 Trip Latest and Greatest

14. Repairing spinal fractures with bone cement might not improve pain in people with osteoporosis

Repairing spinal fractures with bone cement might not improve pain in people with osteoporosis Bone cement procedures may not relieve osteoporosis fracture pain Dissemination Centre Discover Portal NIHR DC Discover Repairing spinal fractures with bone cement might not improve pain in people with osteoporosis Published on 24 July 2018 doi: For people who have spinal fractures as a result of osteoporosis, using a needle to inject bone cement into the broken vertebrae (called vertebroplasty (...) of vertebroplasty on new spinal fractures or severe adverse effects. Current NICE guidance restricts vertebroplasty to individuals with recent fractures which are causing severe on-going pain despite optimal pain management. That guidance takes into account a wider range of evidence than the Cochrane review, such as observational studies. Share your views on the research. Why was this study needed? People with osteoporosis have weakened bones which are more vulnerable to damage, including fractures. Vertebral

2018 NIHR Dissemination Centre

15. Osteoanabolic Agents for Osteoporosis (PubMed)

Osteoanabolic Agents for Osteoporosis 30087947 2018 11 14 2472-1972 2 8 2018 Aug 01 Journal of the Endocrine Society J Endocr Soc Osteoanabolic Agents for Osteoporosis. 922-932 10.1210/js.2018-00118 Medications for osteoporosis are classified as either antiresorptive or anabolic. Whereas antiresorptive agents prevent bone resorption, anabolic agents promote new bone formation. Anabolics should be considered in individuals with severe osteoporosis, failure of alternative osteoporosis agents (...) , intolerability or contraindications to other osteoporosis agents, and glucocorticoid-induced osteoporosis. There are currently two approved anabolic therapies, teriparatide and abaloparatide, and a third anabolic agent, romozosumab, is under review by the US Food and Drug Administration. Teriparatide and abaloparatide are administered as daily subcutaneous injections and have been shown to reduce vertebral and nonvertebral fractures significantly. The most common side effects are headache and nausea

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

16. Osteoporosis to Prevent Fractures: Screening

Osteoporosis to Prevent Fractures: Screening Final Update Summary: Osteoporosis to Prevent Fractures: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 3/6/2018 4:20:40 PM You are here: Final Summary Osteoporosis to Prevent Fractures: Screening Osteoporosis to Prevent Fractures: Screening Release Date: June 2018 Recommendation Summary Population Recommendation Grade Women 65 years and older The USPSTF recommends screening (...) for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older. Postmenopausal women younger than 65 years at increased risk of osteoporosis The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool. See the for information on risk assessment. Men The USPSTF concludes

2018 U.S. Preventive Services Task Force

17. Osteoporosis

Osteoporosis Autosynthesis - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search

2018 Trip Evidence Maps

18. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. (PubMed)

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. Importance: By 2020, approximately 12.3 million individuals in the United States older than 50 years are expected to have osteoporosis. Osteoporotic fractures, particularly hip fractures, are associated with limitations in ambulation, chronic pain and disability, loss of independence, and decreased quality of life, and 21% to 30% of patients who experience a hip fracture die within 1 (...) year. The prevalence of primary osteoporosis (ie, osteoporosis without underlying disease) increases with age and differs by race/ethnicity. With the aging of the US population, the potential preventable burden is likely to increase in future years. Objective: To update the 2011 US Preventive Services Task Force (USPSTF) recommendation on screening for osteoporosis. Evidence Review: The USPSTF reviewed the evidence on screening for and treatment of osteoporotic fractures in men and women, as well

Full Text available with Trip Pro

2018 JAMA

19. How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (PubMed)

How Would You Manage This Patient With Osteoporosis?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Osteoporosis is a skeletal disorder characterized by reduced bone strength that increases the risk for fracture. Approximately 10 million men and women in the United States have osteoporosis, and more than 2 million osteoporosis-related fractures occur annually. In 2016, the American Association of Clinical Endocrinologists issued the "Clinical Practice Guideline (...) for the Diagnosis and Treatment of Postmenopausal Osteoporosis," and in 2017, the American College of Physicians issued the guideline "Treatment of Low Bone Density or Osteoporosis to Prevent Fracture in Men and Women." Both guidelines agree that patients diagnosed with osteoporosis should be treated with an antiresorptive agent, such as alendronate, that has been shown to reduce hip and vertebral fractures. However, there is no consensus on how long patients with osteoporosis should be treated and whether

2018 Annals of Internal Medicine

20. Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study (PubMed)

Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study 29881314 2018 11 14 1179-156X 10 2018 Open access rheumatology : research and reviews Open Access Rheumatol Comparative assessment of fracture risk among osteoporosis and osteopenia patients: a cross-sectional study. 61-66 10.2147/OARRR.S151307 Both osteoporosis and osteopenia remain worldwide public health concerns. They both lead to bone fractures, which can lead to disability (...) and burden on those who are afflicted. To assess and compare fracture risk between these two groups of patients. Our cross-sectional study included 82 patients (46 with osteoporosis and 36 with osteopenia) with an average age of 63±9.33 years, who received treatment at the Clinic for Medical Rehabilitation, Clinical Center of Vojvodina in Novi Sad, Serbia. The assessment of the fracture risk was executed by applying the Fracture Assessment Risk (FRAX) index (an algorithm developed by the World Health

Full Text available with Trip Pro

2018 Open access rheumatology : research and reviews